1383. In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of NOSO-502, a First-in-Class Odilorhabdin Antibiotic, Against E. coli (EC) and K. pneumoniae (KPN) in the Murine Neutropenic Thigh Model
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
1383. In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of NOSO-502, a First-in-Class Odilorhabdin Antibiotic, Against E. coli (EC) and K. pneumoniae (KPN) in the Murine Neutropenic Thigh Model
Contributor:
Zhao, Miao;
Lepak, Alexander J;
Andes, David R
Description:
<jats:title>Abstract</jats:title>
<jats:sec>
<jats:title>Background</jats:title>
<jats:p>NOSO-502 is a novel, first-in-class Odilorhabdin antibiotic targeting bacterial protein translation, with potent in vitro activity against Enterobacteriaceae including strains with MDR or CRE-phenotype. The goal of this study was to determine the PK/PD characteristics of NOSO-502 using the murine thigh infection model against a diverse group of EC and KPN strains.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Methods</jats:title>
<jats:p>Twelve strains (6 EC, 6 KPN) were utilized, including those with tetracycline or β-lactam resistance. MICs were determined by CLSI Methods. Single dose murine plasma PK of NOSO-502 was determined after administration of 7.81, 31.25, 125 and 500 mg/kg by SC route. Dose fractionation (DF) study was used to determine which PK/PD index was associated with efficacy. The relationship between each PK/PD indices and CFU outcome data were analyzed using the sigmoid Emax (Hill) model with nonlinear regression. Treatment studies were then performed with the remaining 11 strains. Four-fold increasing NOSO-502 doses (3.91–1,000 mg/kg/6 hours SC route) were administered. Treatment data and AUC/MIC was analyzed to determine AUC/MIC targets associated with net stasis and 1-log kill (when achieved) for all strains.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results</jats:title>
<jats:p>MICs ranged from 1 to 4 mg/L. PK ranges for doses included: Cmax 1.5–85 mg/L, AUC0-∞ 1.9–352 mg hour/L, T1/2 0.4–1.1 hour. DF regression analysis: AUC/MIC R2 0.86, Cmax/MIC R2 0.70, T &gt; MIC R2 0.77. Against each of the 12 strains there was dose-dependent activity and net stasis was achieved against all strains, with maximal activity of 1–2 log killing in EC and almost 3 log killing in KPN. The 24 hours stasis total and free drug PD targets are shown (table). 1-log kill targets were determined for KPN and noted at a median 24 hours fAUC/MIC of 11.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusion</jats:title>
<jats:p>NOSO-502 demonstrated in vivo potency against a diverse group of EC and KPN strains including those with resistance to tetracycline and β-lactams. The PK/PD index predictive of efficacy is AUC/MIC. Stasis 24 hours AUC/MIC targets were numerically low for KPN and EC. This data suggest that NOSO-502 is a promising novel agent and these targets will provide a basis for developing human dosing regimens to optimize efficacy.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Disclosures</jats:title>
<jats:p>M. Zhao, Nosopharm: Research Contractor, Research support. A. J. Lepak, Nosopharm: Research Contractor, Research support. D. R. Andes, Nosopharm: Research Contractor, Research support.</jats:p>
</jats:sec>